Dosage Lookup
Peptides
Moderate
consensus
Consensus Protocol
Dosage
- There is no single 'peptide dose' — it is entirely molecule-specific and set by a prescriber
- The shared principle across experts is the smallest effective dose, not the biggest, and only for a peptide with a real indication
Form
- Most therapeutic peptides are injectable (subcutaneous)
- a few are nasal, oral, or topical (e
- g
- , GHK-Cu in skincare)
- The FDA-approved options — PT-141, tesamorelin — come from a licensed pharmacy
- 'Research-only' vials do not
Timing
- Cycled, not continuous
- Several experts caution explicitly against indefinite use of unproven peptides — BPC-157's theoretical tumor-growth risk is the clearest example of why 'forever' is the wrong default
Notes
- Physician-prescribed and lab-monitored only
- Avoid gray-market 'research purposes only' vials — they carry LPS/endotoxin contamination, variable purity, and no dosing guarantee
- Build the foundations first: sleep, resistance training, protein, and proven interventions before any exotic peptide (Hyman, Attia)
Expert Positions
What Each Expert Says
Huberman is the panel's anchor on peptides, with two dedicated episodes. In his solo episode he defines the category, lays out the three-tier safety framing, and walks through BPC-157, TB-500/thymosin beta-4, the growth-hormone secretagogues, and melanocortin peptides — repeatedly returning to the need for medical supervision and clean sourcing. His guest episodes add a clinician's enthusiasm (Dr. Craig Koniver) and a careful researcher's caution (Dr. Abud Bakri), including the regulatory reality that the FDA has restricted BPC-157 and CJC-1295.
Unlock Expert Deep Dives
See exactly what each expert recommends — specific dosages, forms, timing protocols, and video citations with timestamps.
Cancel anytime